COVAX-19 Vaccine: Completely blocks virus transmission to non-immune individuals
Clinical Complementary Medicine and Pharmacology
; 1(1) (no pagination), 2021.
Article
in English
| EMBASE | ID: covidwho-2254457
ABSTRACT
Various vaccine platforms are geared against COVID-19 vaccine development to produce immunogens in cells. To design a recombinant protein-based COVID-19 vaccine, Vaxine pty Ltd used computer models of the spike protein and its human receptor, ACE2, to identify how the virus infects human cells. Based on this, the COVAX-19 vaccine is synthesized. It does reduce not only COVID-19 disease but also blocks virus shedding and transmission. Researchers are optimistic that this vaccine candidate could be clinically available soon with sufficient vaccine efficacy with a considerable amount of reduction in vaccination-related side effects.Copyright © 2021
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Clinical Complementary Medicine and Pharmacology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS